In addition, while clinical laboratories are increasingly using next-generation sequencing (NGS) panels for AML stratification/prognosis purposes, it must be emphasized that NGS has specific limitations regarding FLT3-ITD capture and assessment of the FLT3-ITD allelic burden. Here, FLT3 is linked to acute myeloid leukemia.